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Boesenbergia rotunda (L.) Mansf.
Antinociceptive
Anti-inﬂammatory
A B S T R A C T
Boesenbergia rotunda (L.) Mansf. had been traditionally used as herbs to treat pain and rheumatism.
Cardamonin (2′,4′-dihydroxy-6′-methoxychalcone) is a compound isolated from Boesenbergia rotunda (L.)
Mansf.. Previous study had shown the potential of cardamonin in inhibiting the release of pro-inﬂammatory
cytokines such as tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in vitro.
Thus, the possible therapeutic eﬀect of cardamonin in the rheumatoid arthritis (RA) joints is postulated. This
study was performed to investigate the anti-arthritic properties of cardamonin in rat model of induced RA,
particularly on the inﬂammatory and pain response of RA. Rheumatoid arthritis paw inﬂammation was induced
by intraplantar (i.pl.) injection of complete Freund's adjuvant (CFA) in Sprague Dawley rats. Using four doses
of cardamonin (0.625, 1.25, 2.5, and 5.0 mg/kg), anti-arthritic activity was evaluated through the paw edema,
mechanical allodynia and thermal hyperalgesia responses. Enzyme-linked immunosorbent assay (ELISA) was
carried out to evaluate the plasma level of TNF-α, IL-1β, and IL-6. Histological slides were prepared from the
harvested rat paws to observe the arthritic changes in the joints. Behavioral, biochemical, and histological
studies showed that cardamonin demonstrated signiﬁcant inhibition on RA-induced inﬂammatory and pain
responses as well as progression of joint destruction in rats. ELISA results showed that there was signiﬁcant
inhibition in TNF-α, IL-1β, and IL-6 levels in plasma of the cardamonin-treated RA rats. Overall, cardamonin
possesses potential anti-arthritic properties in CFA-induced RA rat model.
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease which causes
chronic systemic joint inﬂammation. RA patients experience swollen
and painful joints which seriously impact their normal well-being.
About 1% of the population worldwide is currently aﬀected by RA
(Gibofsky, 2012). The immune cells attack RA joints by inducing the
release of cytokines such as tumour necrosis factor-alpha (TNF-α) and
interleukins at the synovial membrane, leading to the initiation of
angiogenesis and proliferation of the synovial ﬁbroblasts which causes
the formation of pannus (Holmdahl et al., 2014).
According to the European League against Rheumatism (EULAR)
and American College of Rheumatology (ACR), disease-modifying anti-
rheumatic drugs (DMARDs) such as methotrexate and sulfasalazine are
the primary medication for the patients soon after the onset of RA
(Singh et al., 2015; Smolen et al., 2013) while cocktails of DMARDs
and glucocorticoids are given as the substitutes when the therapeutic
eﬀect of initial prescription wanes oﬀ (f Smolen et al., 2013). The
medical regimens for RA patients keep on changing not only due to the
reduction of their beneﬁcial eﬀects over time, their adverse side eﬀects
which cause morbidity and mortality in patients are seriously con-
sidered as well (Singh et al., 2015). Due to the drawbacks in the
currently available treatments for RA, new drug discovery is of research
interest in order to oﬀer patients with more choices of drugs other than
the three main RA prescriptions (Quan et al., 2008), with fewer or none
adverse eﬀects.
Boesenbergia rotunda (L.) Mansf., also known as ﬁngerroot, is a
rhizomatous plant species in Zingiberaceae family which had long been
established as a medicinal plant family, commonly found in the
Southeast Asian countries and tropical rainforests. (Basak et al.,
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